Julia Scarisbrick

Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal

Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · Journal of Clinical Oncology · 2010 · 845 citations

Medicine, Dermatology, Oncology +17

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Sean Whittaker, Marie‐France Demierre, Ellen J. Kim et al. · Journal of Clinical Oncology · 2010 · 661 citations

Medicine, Oncology, Pharmacology +13

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

H. Miles Prince, Youn H. Kim, Reinhard Dummer et al. · The Lancet · 2017 · 580 citations

Medicine, Hematology, Oncology +12

Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model

Julia Scarisbrick, H. Miles Prince, Maarten H. Vermeer et al. · Journal of Clinical Oncology · 2015 · 421 citations · Full text

Medicine, Dermatology, Oncology +17